184 related articles for article (PubMed ID: 24081592)
1. EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?
Allen PB; Laing G; Connolly A; O'Neill C
BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24081592
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens.
Magro F; Santos-Antunes J; Albuquerque A; Vilas-Boas F; Macedo GN; Nazareth N; Lopes S; Sobrinho-Simões J; Teixeira S; Dias CC; Cabral J; Sarmento A; Macedo G
Inflamm Bowel Dis; 2013 Jul; 19(8):1710-6. PubMed ID: 23574759
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous regression of colonic lymphoma following infliximab and azathioprine withdrawal in patients with Crohn's disease.
Flynn AD; Azar JM; Chiorean MV
Inflamm Bowel Dis; 2013 Apr; 19(5):E69-70. PubMed ID: 23399737
[No Abstract] [Full Text] [Related]
4. Epstein-Barr virus-associated lymphoma in Crohn's disease.
Losco A; Gianelli U; Cassani B; Baldini L; Conte D; Basilisco G
Inflamm Bowel Dis; 2004 Jul; 10(4):425-9. PubMed ID: 15475752
[TBL] [Abstract][Full Text] [Related]
5. Infliximab in ulcerative colitis.
Aberra FN; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease.
Deneau M; Wallentine J; Guthery S; O'Gorman M; Bohnsack J; Fluchel M; Bezzant J; Pohl JF
Pediatrics; 2010 Oct; 126(4):e977-81. PubMed ID: 20837584
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
[TBL] [Abstract][Full Text] [Related]
8. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
Reddy JG; Loftus EV
Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
[TBL] [Abstract][Full Text] [Related]
9. Infliximab therapy in children and adolescents with inflammatory bowel disease.
Veres G; Baldassano RN; Mamula P
Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
[TBL] [Abstract][Full Text] [Related]
10. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.
de Vries HS; van Oijen MG; de Jong DJ
Drug Saf; 2008; 31(12):1135-44. PubMed ID: 19026030
[TBL] [Abstract][Full Text] [Related]
11. EBV-positive mucocutaneous ulcer within colonic diverticulitis mimicking diffuse large B cell lymphoma.
Zanelli M; Zizzo M; Foroni M; De Marco L; Martino G; Ascani S
Ann Hematol; 2019 Jul; 98(7):1795-1797. PubMed ID: 31093707
[No Abstract] [Full Text] [Related]
12. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
13. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
15. Refractory inflammatory bowel disease: is there a role for Epstein-Barr virus? A case-controlled study using highly sensitive Epstein-Barr virus-encoded small RNA1 in situ hybridization.
Pezhouh MK; Miller JA; Sharma R; Borzik D; Eze O; Waters K; Westerhoff MA; Parian AM; Lazarev MG; Voltaggio L
Hum Pathol; 2018 Dec; 82():187-192. PubMed ID: 30120969
[TBL] [Abstract][Full Text] [Related]
16. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL
Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253
[TBL] [Abstract][Full Text] [Related]
17. Safety of infliximab in 10 years of clinical practice.
O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
[TBL] [Abstract][Full Text] [Related]
18. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
19. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.
Miehsler W; Novacek G; Wenzl H; Vogelsang H; Knoflach P; Kaser A; Dejaco C; Petritsch W; Kapitan M; Maier H; Graninger W; Tilg H; Reinisch W;
J Crohns Colitis; 2010 Sep; 4(3):221-56. PubMed ID: 21122513
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
